All In Biotech

Drug Trial Radar · NCT00002582

Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

UKCCCR RANDOMISED TRIAL OF ADJUVANT ENDOCRINE THERAPY AND CHEMOTHERAPY IN WOMEN WITH EARLY BREAST CANCER, THE ADJUVANT BREAST CANCER (ABC) TRIAL

Last checked: Nov 19, 2026Latest source record: Aug 2, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 6,000 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,000

Planned (sponsor's estimate)

Start

Jun 1993

Primary completion

Not stated

Study completion Apr 2007

Sponsor

Lead sponsor
Institute of Cancer Research, United KingdomAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Cancer Research Campaign Clinical Trials Centre; Scottish Cancer Therapy Network; Yorkshire Regional Clinical Trials Research Unit
First posted
Jul 8, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen. Combination chemotherapy uses different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of tamoxifen with or without chemotherapy and/or ovarian ablation in treating women with stage I, stage II, or stage IIIA breast cancer.

Conditions

  • Breast Cancer

Interventions

  • CMF regimenDrug

  • cyclophosphamideDrug

  • doxorubicin hydrochlorideDrug

  • fluorouracilDrug

  • goserelin acetateDrug

  • leuprolide acetateDrug

  • methotrexateDrug

  • tamoxifen citrateDrug

  • oophorectomyProcedure

  • radiation therapyRadiation

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Cancer Research Campaign Trials Unit-Birmingham (CRCTU)

    Birmingham, England, United Kingdom

  • Beatson Oncology Centre

    Glasgow, Scotland, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.